Naproxcinod May Eliminate Blood Pressure Elevations Common With NSAIDs
By Carol Eustice, About.com Guide April 3, 2011
According to the American Journal of Cardiology, a pooled safety analysis concluded that naproxcinod may eliminate blood pressure elevations that are common with other nonsteroidal anti-inflammatory drugs (NSAIDs). Naproxcinod is an investigational nitric oxide-donating cyclooxygenase inhibitor. Last year, the FDA turned down naproxcinod's effort to be approved for the treatment of osteoarthritis, pending further efficacy and safety data.
Specifically, the journal report concluded that "results imply that naproxcinod would be less likely to alter systolic BP control in patients with OA than a conventional nonsteroidal anti-inflammatory drug, particularly in those treated with renin-angiotensin system inhibitor agents." The findings will be helpful when NicOx, the developer of naproxcinod, appeals the FDA decision.